Mn Services Vermogensbeheer B.V. Has $15.36 Million Stake in Moderna, Inc. (NASDAQ:MRNA)

Mn Services Vermogensbeheer B.V. reduced its stake in Moderna, Inc. (NASDAQ:MRNA) by 3.6% in the 4th quarter, Holdings Channel reports. The firm owned 154,400 shares of the company’s stock after selling 5,800 shares during the period. Mn Services Vermogensbeheer B.V.’s holdings in Moderna were worth $15,355,000 as of its most recent filing with the SEC.

Several other institutional investors and hedge funds have also recently added to or reduced their stakes in MRNA. First Pacific Financial bought a new position in Moderna in the 3rd quarter worth approximately $27,000. ICA Group Wealth Management LLC bought a new position in Moderna in the 4th quarter worth approximately $27,000. Arlington Trust Co LLC increased its position in Moderna by 4,833.3% in the 4th quarter. Arlington Trust Co LLC now owns 296 shares of the company’s stock worth $29,000 after buying an additional 290 shares during the period. Stonebridge Capital Advisors LLC increased its position in shares of Moderna by 79.1% during the first quarter. Stonebridge Capital Advisors LLC now owns 283 shares of the company’s stock valued at $49,000 after purchasing an additional 125 shares during the period. Finally, Ancora Advisors LLC increased its position in shares of Moderna by 41.2% during the first quarter. Ancora Advisors LLC now owns 329 shares of the company’s stock valued at $51,000 after purchasing an additional 96 shares during the period. 75.33% of the stock is currently owned by institutional investors and hedge funds.

Moderna Trading Down 1.7 %

NASDAQ MRNA opened at $105.14 on Monday. Moderna, Inc. has a 52 week low of $62.55 and a 52 week high of $163.24. The stock’s 50 day moving average price is $99.86 and its two-hundred day moving average price is $93.53. The company has a debt-to-equity ratio of 0.04, a quick ratio of 3.36 and a current ratio of 3.42.

Moderna (NASDAQ:MRNA) last posted its quarterly earnings data on Thursday, February 22nd. The company reported $0.55 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.78) by $1.33. Moderna had a negative net margin of 68.84% and a negative return on equity of 10.23%. The company had revenue of $2.80 billion for the quarter, compared to the consensus estimate of $2.53 billion. During the same period last year, the company earned $3.61 earnings per share. The firm’s revenue was down 44.9% compared to the same quarter last year. As a group, research analysts forecast that Moderna, Inc. will post -7.48 earnings per share for the current year.

Insider Activity

In other news, President Stephen Hoge sold 15,000 shares of Moderna stock in a transaction that occurred on Tuesday, January 16th. The shares were sold at an average price of $103.90, for a total value of $1,558,500.00. Following the sale, the president now directly owns 1,516,063 shares in the company, valued at $157,518,945.70. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In related news, President Stephen Hoge sold 15,000 shares of the business’s stock in a transaction on Tuesday, January 16th. The shares were sold at an average price of $103.90, for a total transaction of $1,558,500.00. Following the transaction, the president now directly owns 1,516,063 shares in the company, valued at $157,518,945.70. The sale was disclosed in a filing with the SEC, which is available through this link. Also, insider Shannon Thyme Klinger sold 670 shares of the business’s stock in a transaction on Thursday, February 29th. The stock was sold at an average price of $94.57, for a total transaction of $63,361.90. Following the transaction, the insider now owns 8,557 shares in the company, valued at $809,235.49. The disclosure for this sale can be found here. Insiders have sold 94,954 shares of company stock worth $9,966,476 over the last ninety days. Insiders own 15.20% of the company’s stock.

Analyst Ratings Changes

A number of analysts have recently issued reports on the company. Oppenheimer upgraded Moderna from a “market perform” rating to an “outperform” rating and set a $142.00 price objective on the stock in a research report on Tuesday, January 2nd. Needham & Company LLC restated a “hold” rating on shares of Moderna in a research report on Thursday. Jefferies Financial Group restated a “buy” rating and set a $125.00 price objective on shares of Moderna in a research report on Tuesday, April 9th. William Blair reaffirmed a “market perform” rating on shares of Moderna in a research note on Monday, April 1st. Finally, Royal Bank of Canada reaffirmed an “outperform” rating and issued a $125.00 price target on shares of Moderna in a research note on Thursday, March 28th. Two equities research analysts have rated the stock with a sell rating, nine have assigned a hold rating and six have issued a buy rating to the company. According to MarketBeat, the stock currently has a consensus rating of “Hold” and a consensus price target of $126.49.

Moderna Company Profile

Moderna, Inc, a biotechnology company, discovers, develops, and commercializes messenger RNA therapeutics and vaccines for the treatment of infectious diseases, immuno-oncology, rare diseases, autoimmune, and cardiovascular diseases in the United States, Europe, and internationally. Its respiratory vaccines include COVID-19, influenza, and respiratory syncytial virus, spikevax, and hMPV/PIV3 vaccines; latent vaccines comprise cytomegalovirus, epstein-barr virus, herpes simplex virus, varicella zoster virus, and human immunodeficiency virus vaccines; public health vaccines consists of Zika, Nipah, Mpox vaccines; and infectious diseases vaccines, such as lyme and norovirus vaccines.